Dr. James Song reviews the latest long-term safety data on topical and oral JAK inhibitors for managing atopic dermatitis**.**
Topics Covered:
Long-term safety of JAK inhibitors in AD
Topical vs. oral JAK inhibitor profiles
Monitoring and risk considerations
Updates in safety data for chronic use
Explore Related Resources:
Christopher Bunick, MD, PhD, an associate professor of dermatology at Yale School of Medicine in New Haven, Connecticut, discusses a poster presentation comparing the itch
Kara Mudd reviews findings from the Phase 3 TRuE-AD3 study evaluating topical ruxolitinib in children aged 2 to <12 years with atopic dermatitis. The discussion
Dr. Shahriari reviews the FDA’s decision to remove certain “black box” warnings for hormone replacement therapy (HRT) and discusses how this shift may influence treatment
Dr. Johann Gudjonsson discusses how spesolimab may reduce low-grade inflammation between flares in patients with generalized pustular psoriasis (GPP). Topics Covered: Subclinical inflammation in GPP
Dr. Lisa Swanson highlights three effective nonsteroidal topical therapies for managing atopic dermatitis in both pediatric and adult patients. Topics Covered: Nonsteroidal topical options for
Dr. Raj Chovatiya presents long-term data on upadacitinib’s ability to maintain skin clearance and itch relief in atopic dermatitis patients over 140 weeks. Topics Covered:
Dr. Diego Ruiz Dasilva reviews real-world data showing the safety and efficacy of combining topical ruxolitinib with systemic therapies in atopic dermatitis care. Topics Covered:
Andrew Mastro, MS, PA-C, addresses the psychosocial impact of chronic hand eczema and highlights emerging treatments like biologics and JAK inhibitors. Topics Covered: Quality of
Andrew Mastro, MS, PA-C, addresses the psychosocial impact of chronic hand eczema and highlights emerging treatments like biologics and JAK inhibitors. Topics Covered: Quality of
Dr. Naiem Issa shares real-world evidence showing how ruxolitinib cream may reduce treatment costs and productivity loss in patients with atopic dermatitis. Topics Covered: Economic
Dr. Diego Ruiz Dasilva highlights real-world data showing oral JAK inhibitors can safely and effectively achieve treatment targets in elderly patients with AD. Topics Covered:
Dr. Lisa Swanson shares insights on maximum-use data for ruxolitinib cream in children ages 2–11 with atopic dermatitis, highlighting safety and efficacy. Topics Covered: Ruxolitinib
Lisa Swanson, MD, JCAD’s Section Editor of Pediatric Dermatology, shares her thoughts on new research evaluating maximum-use conditions for topical ruxolitinib cream in pediatric patients
Dr. Michael Cameron discusses 52-week results showing rapid and lasting improvements in itch and quality of life with upadacitinib plus topical steroids. Topics Covered: Combination
Dr. James Song highlights the need for personalized approaches in atopic dermatitis care to predict treatment response and reduce trial-and-error prescribing. Topics Covered: Personalization in
Melodie Young, MSN, RN, ANP-C, discusses treating young children with atopic dermatitis and counseling caregivers on potential side effects. Topics Covered: Pediatric atopic dermatitis treatment
